ASPIRA PATHLAB & DIAGNOSTICS | GIAN LIFE CARE | ASPIRA PATHLAB & DIAGNOSTICS / GIAN LIFE CARE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -13.6 | 19.8 | - | View Chart |
P/BV | x | 2.6 | 1.5 | 171.0% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
ASPIRA PATHLAB & DIAGNOSTICS GIAN LIFE CARE |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
GIAN LIFE CARE Mar-22 |
ASPIRA PATHLAB & DIAGNOSTICS / GIAN LIFE CARE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 145 | 51.7% | |
Low | Rs | 26 | 12 | 209.4% | |
Sales per share (Unadj.) | Rs | 14.0 | 15.4 | 91.2% | |
Earnings per share (Unadj.) | Rs | -0.1 | 4.2 | -2.0% | |
Cash flow per share (Unadj.) | Rs | 1.5 | 4.5 | 32.0% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 12.4 | 13.6 | 91.3% | |
Shares outstanding (eoy) | m | 10.29 | 10.34 | 99.5% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 5.1 | 70.2% | |
Avg P/E ratio | x | -583.7 | 18.6 | -3,137.9% | |
P/CF ratio (eoy) | x | 34.6 | 17.3 | 199.9% | |
Price / Book Value ratio | x | 4.1 | 5.8 | 70.1% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 518 | 813 | 63.7% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 13 | 426.3% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 159 | 90.8% | |
Other income | Rs m | 3 | 5 | 63.6% | |
Total revenues | Rs m | 148 | 164 | 89.9% | |
Gross profit | Rs m | 16 | 69 | 23.0% | |
Depreciation | Rs m | 16 | 3 | 485.0% | |
Interest | Rs m | 4 | 13 | 33.3% | |
Profit before tax | Rs m | -1 | 59 | -1.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 15 | 0.0% | |
Profit after tax | Rs m | -1 | 44 | -2.0% | |
Gross profit margin | % | 11.0 | 43.5 | 25.4% | |
Effective tax rate | % | 0 | 25.3 | -0.0% | |
Net profit margin | % | -0.6 | 27.4 | -2.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 104 | 56.2% | |
Current liabilities | Rs m | 16 | 69 | 22.9% | |
Net working cap to sales | % | 29.5 | 22.1 | 134.0% | |
Current ratio | x | 3.7 | 1.5 | 244.9% | |
Inventory Days | Days | 88 | 207 | 42.5% | |
Debtors Days | Days | 590 | 407 | 145.1% | |
Net fixed assets | Rs m | 115 | 126 | 90.9% | |
Share capital | Rs m | 103 | 103 | 99.5% | |
"Free" reserves | Rs m | 25 | 37 | 66.7% | |
Net worth | Rs m | 128 | 140 | 90.9% | |
Long term debt | Rs m | 10 | 19 | 51.4% | |
Total assets | Rs m | 173 | 231 | 75.2% | |
Interest coverage | x | 0.8 | 5.7 | 13.9% | |
Debt to equity ratio | x | 0.1 | 0.1 | 56.5% | |
Sales to assets ratio | x | 0.8 | 0.7 | 120.7% | |
Return on assets | % | 1.9 | 24.4 | 7.8% | |
Return on equity | % | -0.7 | 31.2 | -2.2% | |
Return on capital | % | 2.4 | 44.7 | 5.4% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 0 | - | |
Net fx | Rs m | 0 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | 58 | -0.2% | |
From Investments | Rs m | 2 | -41 | -3.9% | |
From Financial Activity | Rs m | -9 | 7 | -139.1% | |
Net Cashflow | Rs m | -8 | 23 | -33.7% |
Indian Promoters | % | 18.7 | 48.5 | 38.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.3 | 51.5 | 157.7% | |
Shareholders | 1,512 | 2,426 | 62.3% | ||
Pledged promoter(s) holding | % | 0.0 | 26.5 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS METROPOLIS HEALTHCARE NARAYANA HRUDAYALAYA KIMS
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | GIAN LIFE CARE | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 1.27% | 1.14% | -0.23% |
1-Month | -2.29% | -7.12% | -0.32% |
1-Year | -3.03% | -15.57% | 53.43% |
3-Year CAGR | 2.29% | 44.31% | 14.83% |
5-Year CAGR | -1.66% | 15.43% | 19.74% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the GIAN LIFE CARE share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.7% stake in the company. In case of GIAN LIFE CARE the stake stands at 48.5%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of GIAN LIFE CARE.
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
GIAN LIFE CARE paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of GIAN LIFE CARE.
For a sector overview, read our pharmaceuticals sector report.
Asian stocks got off to a positive start on Monday ahead of the Federal Reserve's policy meeting later in the week.